Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
Phase 2
Completed
NCT04484142
| Condition | Non-small Cell Lung Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Daiichi Sankyo |
|---|
| Status | Completed |
|---|
| Enrollment | 137 participants |
|---|
| Interventions | DS-1062a |
|---|
| Start date | Mar 30, 2021 |
|---|
| Completion date | Mar 10, 2023 |
|---|
| Results posted | Apr 3, 2024 |
|---|
Summary
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.
Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR)
From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months. · percentage of participants
| Dato DXd 6.0 mg/kg Q3W | 35.8 percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.